Singapore, Feb. 20 -- Brexogen, a leading biotechnology company specialising in exosome-based therapeutics, has announced a technology transfer and licensing agreement with BMI Korea for BxC-I17e, an innovative exosome-based injectable therapeutic.

This agreement marks the first major licensing deal for an exosome therapeutic in Korea, signifying a major milestone in the commercialization of exosome-based medicines.

BxC-I17e is a key asset in Brexogen's pipeline and is currently undergoing clinical trials in the United States for atopic dermatitis. Recognising its broader therapeutic potential, BMI Korea has secured rights to expand its development into potential indications excluding immunological indications, covering both domestic an...